INTRODUCTION
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy (genetic alteration of the white matter) that affects brain chloride and fluid homeostasis (1) . MRI of patients shows diffuse signal abnormality, swelling of the cerebral white matter and the presence of subcortical cysts, mainly in the anterior temporal regions (2, 3) . Studies from an MLC patient brain biopsy revealed that the major phenotype of the disease was myelin vacuolation (4) . These results, together with proton magnetic spectroscopic resonance data (5, 6) , suggested that MLC is caused by disturbed fluid homeostasis.
MLC1 was the first gene to be identified in MLC patients (7) and accounts for MLC in most patients. In mouse and human tissue, high MLC1 levels were present in astroglial -astroglial junctions and ependymal cells in blood -brain and CSF -brain barriers, apart from astrocytic junctions of Bergmann glia in the cerebellum (8 -11) . Thus, it has been proposed that MLC has an astrocytic origin (12) , based on the fact that MLC1 is mostly expressed in astrocytes. In agreement with this hypothesis, depletion of MLC1 in astrocytes causes vacuolation, a phenotype that was also observed after re-examination of a MLC patient's brain biopsy (13) , which showed previously only myelin vacuoles. Interestingly, reduction in MLC1 in astrocytes and in lymphoblast cell lines from MLC patients was found to be associated with a reduced activity of volume-regulated anion currents (VRAC) by an unknown mechanism (14) . In parallel, the rate of regulatory volume decrease after cell swelling was reduced in MLC1-depleted cells (14) . It has also been suggested that MLC1 could interact functionally with the b-subunit of the Na + /K + ATPase (15) and with the TRPV4 ion channel (16) . However, the role of MLC1 is still completely unknown, and whether these interactions are related to the effects of MLC1 depletion on VRAC activity is unknown.
GLIALCAM was recently identified as a second gene mutated in MLC (17) . It was demonstrated that GlialCAM functions as an escort molecule necessary to target MLC1 to cell -cell junctions (18) . Moreover, the changed localization of the MLC1/Glial-CAM complexes seems to play an important role in the development of the disease, as most GLIALCAM mutations impair the correct trafficking of GlialCAM and MLC1 to astrocyteastrocyte junctions (17, 18) .
Histological studies in tissue indicated that GlialCAM is mostly localized in astrocyte -astrocyte junctions where it co-localizes with MLC1 (17) , but also in oligodendrocyte processes (19, 20) . Proteomic studies searching for additional Glial-CAM protein partners revealed that GlialCAM also acts as an auxiliary subunit of the ClC-2 chloride channel, targeting it to astrocytic cell junctions and modifying its functional properties (20) . Similar to its effect on MLC1 targeting, GLIALCAM MLC-related mutations also impair the trafficking of ClC-2 to cell junctions. Strikingly, Clcn2 KO mice also displayed similar vacuolation to what is seen in MLC patients (21) , suggesting its involvement in the pathogenesis of MLC. However, no CLCN2 mutations were detected in MLC patients (22) and no direct protein interaction was found between MLC1 and ClC-2 (13, 20) . Thus, the involvement of ClC-2 in MLC disease is unclear. However, very recently, it has been shown that CLCN2 mutations may cause certain forms of a human leukodystrophy characterized by white matter oedema (23) .
Dominant mutations in GLIALCAM cause other type of disease called MLC2B characterized by transient features of MLC (24) . Similar to the recessive GLIALCAM mutations, also dominant mutations cause MLC1 and ClC-2 trafficking defects (17, 18, 20) . It is still unknown why dominant mutations and not recessive mutations show a trafficking dominant behavior. Furthermore, dominant mutations are also associated with different clinical phenotypes than MLC1 mutations, while the clinical and MRI phenotypes related to recessive MLC1 and GLIALCAM mutations are the same.
In the present work, we have analyzed biochemically and functionally what the consequences of a reduced GlialCAM expression are, and compared them with the effects of a reduced MLC1 expression. The effect of GLIALCAM and MLC1 mutations was also addressed. The results obtained indicate that Glial-CAM is necessary for MLC1 protein expression, and its reduction affects the activity of VRAC, which may cause astrocyte vacuolation. Thus, this work extends the role of GlialCAM as a chaperone of MLC1 needed for proper VRAC activation. In addition, based on functional data obtained, we suggest that a therapeutic strategy aimed to recover the surface expression of MLC1 and/or the activation of VRAC currents can be envisaged as beneficial for all MLC patients.
RESULTS

Experimental approach to create an astrocyte cell model with reduced GlialCAM expression
To study the cellular effects of GlialCAM ablation, adenoviral vectors expressing two distinct shRNA (1 or 2) against rat Glial-CAM with the fluorescent protein EmGFP, allowing visualization of transduced cells, were produced. An adenoviral vector expressing non-targeted or scrambled shRNA (SCR) was used as a control. RT-qPCR experiments performed 7 days after Glial-CAM shRNA infection of astrocytes demonstrated that endogenous GlialCAM mRNA levels were profoundly depleted (Fig. 1A) . Accordingly, western blot (WB) analysis indicated that the GlialCAM protein level was reduced by 80% when compared with the control SCR ( Fig. 1B and Supplementary Material, Fig. S1 ). Immunofluorescence experiments confirmed no detectable GlialCAM protein in shRNA-treated cells (Fig. 1C) . Both types of experiments (WB and immunofluorescence) also demonstrated the specificity of the GlialCAM antibodies used (17) . As an additional control, to exclude side effects of shRNAs, we also complemented with an adenovector expressing human C-terminally flag-tagged GlialCAM, which was resistant to the rat-specific GlialCAM shRNAs (Fig. 1B and C) .
Reduction in GlialCAM expression led to intracellular retention and reduced expression of MLC1 in rat astrocytes
We studied the consequences of reduced GlialCAM expression at the mRNA, protein and subcellular localization of MLC1 (Fig. 2) . As a specificity control, we monitored the expression and subcellular localization of a subset of proteins associated with tight, adherent and gap junctions. Knockdown of Glial-CAM led to a reduction (about 30%) of the MLC1 mRNA levels (not significant) ( Fig. 2A) . However, the MLC1 protein abundance was reduced to 60% of wild-type values ( Fig. 2B and Supplementary Material, Fig. S1 ), which cannot be explained by the reduction in the mRNA levels. Protein levels of some junction proteins were not altered, excluding nonspecific effects (Fig. 2B and data not shown) .
Importantly, while MLC1 was predominantly confined to an intracellular perinuclear compartment (Fig. 2D , arrowheads) in astrocyted depleted of GlialCAM, MLC1 remained associated with cell -cell junctions in astrocytes transduced with control shRNA (Fig. 2C) . Furthermore, the junctional localization of MLC1 was recovered after complementation of the astrocytes with flag-tagged human GlialCAM cDNA (Fig. 2E) , which was resistant to this shRNA ( Fig. 1 and Supplementary Material,  Fig. S1 ). Therefore, altered processing and decreased stability of the MLC1 may account for the cellular phenotype of MLC1 rather than non-specific effects of the shRNA. Additional control experiments also showed that localization of some junction proteins was not changed in GlialCAM-depleted astrocytes (Supplementary Material, Fig. S2 and data not shown).
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GlialCAM improves the protein stability and surface expression of MLC1 variants containing MLC-related mutations
The above results suggest that GlialCAM may function as a chaperone needed for correct MLC1 folding and expression. If this is the case, GlialCAM over-expression may correct the localization of MLC1 variants containing MLC-related mutations, which primarily affect MLC1 protein folding (25) . To test this hypothesis, we constructed adenoviruses expressing a HA-tagged human MLC1 variant containing the MLC-related mutations Pro92Ser (P92S) or Ser246Arg (S246R), and they were used to transduce rat astrocytes with or without GlialCAM. The immunostaining of the mutant MLC1-P92S showed a perinuclear intracellular distribution in astrocytes (Fig. 3A) , similar to the endoplasmatic reticulum (ER) (25) . However, co-expression with GlialCAM led to a re-distribution of the P92S variant to astrocyte -astrocyte junctions (Fig. 3B left, arrowheads), co-localizing with GlialCAM (Fig. 3B, Using a chemiluminescence-based cell surface ELISA assay, the MLC1 cell surface density was determined as a function of GlialCAM expression, taking advantage of the extracellular HA epitope. The MLC1-P92S has an 80% reduced cell surface expression relative to its wild-type counterpart (Fig. 3C ). Glial-CAM over-expression increased the relative surface-expression levels of the MLC1-P92S in rat astrocytes (Fig. 3D) . The Figure 1 . Adenovector-mediated knockdown of GlialCAM in primary astrocytes. (A) RT-qPCR experiments using specific primers to detect rat GLIALCAM mRNA. Data represent the ratio of mRNA fold change versus the SCR control (mean + SEM) of at least four different astrocyte preparations either treated at MOI 10 with SCR (scrambled) or with 2 different shRNAs against GLIALCAM. Both shRNA Glial1 and Glial2 (see Materials and Methods) caused almost complete inhibition of mRNA expression.
* * P , 0.01 (B) Astrocytes (untreated or transduced at MOI 10 with the shRNA indicated during 7 days, or complemented with adenovirus expressing flag-tagged human GlialCAM at MOI 2 during 2 days) were analyzed by WB using antibodies against GlialCAM. The GlialCAM antibodies used were able to detect the rat and human GlialCAM proteins. b-Actin was used as a loading control. Other different experiments gave similar results (n ¼ 5). (C) Control or astrocytes transduced with the adenovirus indicated were fixed and processed for immunofluorescence using antibodies against GlialCAM. Transduced cells were visualized by the positive GFP signal. GlialCAM signal in astrocyte-astrocyte processes was detected in control cells and in cells transduced with the SCR shRNA but not in cells transduced with the shRNA1 against GlialCAM. In the panels below, cells were co-transduced with an shRNA against GlialCAM and flag-tagged human GlialCAM (resistant to shRNA) and immunofluorescence was performed using antibodies against the flag epitope or GlialCAM. Scale bar: 20 mm.
increase in surface levels detected by this method was moderate but significant. It may be that the surface levels of MLC1 quantified by this assay in astrocytes were underestimated, due to a possible masking of the extracellular HA epitope present in MLC1 by GlialCAM in astrocyte-astrocyte junctions, as happened in other membrane proteins with accessory subunits (26) .
To assess whether GlialCAM can influence MLC1 stability, the disappearance kinetics of the cellular pool was monitored by WB during a cycloheximide chase (CHX). The MLC1-P92S variant showed significantly reduced stability as demonstrated by the accelerated removal of the mutant upon translation termination with CHX ( Fig. 3E and F) . Co-expression with GlialCAM considerably improved the protein stability of the mutated P92S variant and also of the wildtype MLC1 protein.
Knockdown of GlialCAM affects MLC1 protein expression also in HeLa cells
The above results indicate that GlialCAM has two important functions. On the one hand, as reported previously, it is necessary to target MLC1 to cell -cell junctions (18, 20) . On the other hand, GlialCAM is necessary to stabilize MLC1 and this stabilization is important for translocation to the plasma membrane. This second role was unexpected, as MLC1 localization at the plasma membrane was detected without GlialCAM expression in HeLa cells. To explain this controversy, we hypothesized that GlialCAM is endogenously expressed in HeLa cells at low levels. Importantly, GlialCAM protein could be detected at the plasma membrane, using a monoclonal antibody directed against extracellular GlialCAM by a chemiluminescence-based ELISA assay (Fig. 4A) . Transfection of two independent shRNAs against GlialCAM reduced the antibody signal, confirming that the plasma membrane signal detected by the antibody was due to GlialCAM (Fig. 4A ).
To address whether the stabilization effect of GlialCAM in MLC1 could be also observed in HeLa cells, we transfected HeLa cells with wild-type MLC1 or MLC-related mutant variants P92S (PS) or C326R (CR) together with and unrelated shRNA as a control or shRNAs against GlialCAM, and assayed the cellular and surface MLC1 expression by immunoblotting and cell surface ELISA, respectively. Knockdown of GlialCAM reduced total ( Fig. 4B ) and cell surface (Fig. 4C ) expression of all MLC1 variants, including the wild-type MLC1, as observed in rat astrocytes. Considering that GlialCAM and MLC1 physically interact [revealed by split-TEV or FRET studies (18) ], these data strongly suggest that GlialCAM exerts a stabilizing effect on MLC1, which is independent of the cell system studied.
Effect of GlialCAM MLC-related variants on MLC1 expression
GlialCAM variants containing MLC-related mutations affect GlialCAM and MLC1 trafficking to cell junctions, without substantially interfering with GlialCAM expression or the biochemical interaction between GlialCAM/MLC1 (17, 18, 20) . We thus addressed whether GLIALCAM mutations can compromise MLC1 stabilization in astrocytes. To this aim, we first depleted endogenous GlialCAM in astrocytes by adenovirus-mediated RNA interference, and then complemented with wild-type Glial-CAM wild-type or two mutant variants, Arg92Gln (R92Q), found in MLC2A patients, or Arg92Trp (R92W), found in MLC2B patients. As a control for protein expression, we complemented with MLC1. Astrocytes were analyzed by WB or immunofluorescence ( Fig. 5 and Supplementary Material, Fig. S1 ). Knockdown of GlialCAM reduced both GlialCAM and MLC1 expression ( Fig. 5A and Supplementary Material, Fig. S1 ), and led to a mislocalization of MLC1 to an intracellular compartment (Fig. 5B) . After knockdown of endogenous GlialCAM, complementation with human GlialCAM rescued MLC1 protein expression ( Fig. 5A and Supplementary Material, Fig. S1 ) and junctional localization (Fig. 5C) .
Complementation with GlialCAM variants containing the mutations R92Q or R92W also rescued MLC1 protein expression ( Fig. 5A and Supplementary Material, Fig. S1 ). However, Volume-regulated chloride currents are affected in MLC1-and GlialCAM-depleted astrocytes
Lack of MLC1 in rat astrocytes or in lymphoblast cell lines obtained from MLC patients have been related with a defective activation of VRAC (14), whose molecular identity is still unknown (27) . We next addressed whether lack of GlialCAM may also affect VRAC currents. Previous electrophysiological studies addressing VRAC currents were performed in mild trypsin-treated astrocytes (14) . As this assays needed an enzymatic treatment to round astrocytes potentially leading to other effects related with the trypsin treatment (28), we switched to dB-cAMP-treated astrocytes that are already rounded due to the elongation of processes (29) . We focused only in changes in VRAC activity, taking advantage of the fact that not all astrocytes express ClC-2 mRNA in isotonic conditions (30) , but most express VRAC currents in hypotonic conditions. In both cases, reduction in MLC1 or GlialCAM led to a dramatic decrease of VRAC activity of 80%, although it was still detectable (Fig. 6 ).
Lack of GlialCAM and MLC1 causes astrocyte vacuolation
Lack of MLC1 in astrocytes and in MLC patients caused the appearance of vacuoles in the cytoplasm of astrocytes [ (13) Astrocytes were transduced with adenoviruses expressing MLC1 wild-type or MLC1 containing the MLC-related mutation P92S alone (C) or in combination with GlialCAM (D). MLC1 constructs have an extracellular HA epitope. Plasma membrane levels were measured using a luminescence-based method, as described in Materials and Methods, and they were normalized to the level of the wild-type MLC1 in each condition. The inset shows an overview of the method. Data correspond to the average of three independent experiments. * P , 0.05, comparing the levels of the mutant at the plasma membrane with or without GlialCAM. (E and F) Astrocytes were transduced with adenoviruses expressing MLC1 wild-type or MLC1 containing the MLC-related mutation P92S alone or in combination with GlialCAM. 48 h after transduction, cells were treated or not with cycloheximide (CHX, 100 mg/ml) at the times indicated. Cells extracts were obtained, and the remaining protein was analyzed by western-blot against the HA epitope. b-Actin detection was used as a loading control. The result is a representative experiment of four with similar results. In (F), a summary of the quantification of all experiments using ImageJ software is shown. To quantify signals by WB, we performed at least three expositions of all WBs, to ensure linearity. The signal is normalized to the value at time 0 for each of the experimental groups. The stability of the mutant P92S increased significantly when co-expressed with GlialCAM (P , 0.01).
Human Molecular
GlialCAM also led to astrocyte vacuolation (Fig. 7C) . Vacuoles appearing in MLC1 or GlialCAM-depleted astrocytes were also of endosomal origin, as revealed by staining with the endodomal protein marker EEA1 (early-endosomal antigen 1) ( Fig. 7B and C) . We next aimed to correlate if vacuolation was directly linked to an increase in intracellular water. Treatment of astrocytes for 24 h with a hypoosmotic medium induced the appearance of water vacuoles of endosomal origin [(15) and Fig. 7D ]. To test if a defective VRAC activity causally can contribute to the vacuolation phenotype, we inhibited VRAC activity, indirectly by attenuating the chloride gradient or directly. This was accomplished by incubating astrocytes with Bumetanide (Fig. 7E) , which blocks sodium/potassium/chloride co-transporters (31-34), or by DCPIB (Fig. 7F) , the most specific VRAC inhibitor known (35) . Both treatments led to the appearance of vacuoles of endosomal origin. In order to correlate the biochemical and electrophysiological data with the vacuolation phenotype, we quantified the number of cells containing vacuoles for all experimental groups (see Materials and Methods). Quantification of the vacuolation phenotype in cells treated with Bumetanide or DCPIB revealed a similar degree of defect as cells treated with the shRNAs against MLC1 or GlialCAM (Fig. 8 and Supplementary Material,  Fig. S4) [Bumetanide, 15.4+2.3% (4 independent exp, 1033 cells); DCPIB, 18.8+2.9% (4 independent exp, 1226 cells)].
Recovery of MLC1 in junctions rescued the vacuolation defect and VRAC activation
The astrocyte vacuolation caused by the lack of GlialCAM was rescued with complementation with human GlialCAM (Fig. 8A and Supplementary Material, Fig. S4 ). However, 
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Human Molecular Genetics, 2013, Vol. 22, No. 21 Figure 6 . VRAC activity is reduced in astrocytes with reduced expression of MLC1 and GlialCAM. Representative family of whole-cell chloride currents in dbcAMPtreated cultured neocortical astrocytes transduced with shRNA scrambled or shRNA against MLC1 or GlialCAM, elicited by the pulse protocol shown in the inset. Astrocytes that did not show ClC-2-like currents in isotonic conditions were selected. They correspond to about 60% of recorded cells. In about 85% of these cells do not having ClC-2 current in isotonic conditions, application of a hypotonic solution activated VRAC current. As expected, these currents were blocked by DCPIB, but not with iodide replacement (data not shown). The plot shows average steady-state current-voltage relationship of dbcAMP-treated astrocytes transduced with shRNA SCR (circles), shRNA MLC1 (filled circles) or shRNA GlialCAM (triangles) in isotonic and hypotonic conditions. Results corresponds to n ¼ 15 for shRNA SCR, n ¼ 14 for shRNA MLC1 and n ¼ 14 for shRNA GlialCAM. * P , 0.05 t-test versus scramble for both MLC1 and GlialCAM groups. Figure 7 . Similarities between the vacuolation induced by the lack of GlialCAM and the inhibition of VRAC activity. (A-C) Primary cultures of astrocytes were transduced with adenovectors expressing shRNA SCR, shRNA against MLC1 or shRNA against GlialCAM. After 7 days, cells were fixed and immunostained using antibodies against early-endosomal antigen 1 (EEA1). In (D-F), cells were transduced with adenovector expressing shRNA SCR and incubated with 50 mM bumetanide during 7 days (D) or 10 mM DCPIB during 7 days (E) or with a hypo-osmotic medium during 24 h (F). Cells were then fixed and immunostained using antibodies against EEA1. Green signal corresponds to GFP which is expressed together with the shRNA. Scale bar: 20 mm.
Human Molecular Genetics, 2013, Vol. 22, No. 21 4411 complementation with GlialCAM containing the MLC-related mutations R92Q or R92W, or further expression of MLC1 did not rescue the vacuolation defect (Fig. 8A ). In agreement with these cellular defects, localization of over-expressed human MLC1 in GlialCAM-depleted astrocytes was detected mostly intracellularly (Supplementary Material, Fig. S5 ). Similarly, vacuolation caused by the lack of MLC1 was rescued by expressing MLC1 or GlialCAM together with MLC1 (Fig. 8B) . However, further expression of GlialCAM did not rescue the vacuolation phenotype. Rescue of MLC1 expression by MLC1 containing MLC-related mutations also failed to counteract the vacuolation phenotype (Fig. 8B) , probably due to its intracellular localization (Fig. 3) . However, restoring the localization of these proteins in junctions (Fig. 3) after co-expressing with GlialCAM successfully suppressed the vacuolation (Fig. 8B) .
We next addressed whether the vacuolation could be correlated with changes in VRAC activity. Over-expression of MLC1 in dB-cAMP-treated astrocytes increased VRAC activity [ Fig. 8C and (14) ]. However, over-expression of GlialCAM alone or MLC1 containing the MLC-related mutation S246R did not increase VRAC activity [ Fig. 8C and (14) ]. In agreement with the rescue of the vacuolation defect, over-expression of MLC1 S246R together with GlialCAM also increased VRAC activity (Fig. 8C) . Therefore, we suggest that defective VRAC activity may be directly linked to astrocyte vacuolation. 
* * * P , 0.001 compared with shRNA MLC1. The background of cells with vacuoles of shRNA SCR (MOI 5) is 5.38 + 1.23%. (C) Representative traces at +80 mV of whole-cell chloride currents in isotonic (black) or hypotonic conditions (grey) elicited by the pulse protocol showed in the inset, in dbcAMP-treated cultured neocortical astrocytes transduced with shRNA scrambled or adenoviruses over-expressing MLC1, GlialCAM, MLC1 S246R or GlialCAM + MLC1 S246R. Astrocytes that did not show ClC-2 currents in isotonic conditions were selected. The plot shows average conductance values at +80 mV in hypotonic conditions. Results correspond to n ¼ 9 for shRNA SCR, n ¼ 8 for MLC1, n ¼ 5 for GlialCAM, n ¼ 9 for MLC1 S246R and n ¼ 9 for GlialCAM + MLC1 S246R.
* P , 0.05 t-test versus. Scramble for all groups. Differences in the kinetics of inactivation were observed between groups in an unrelated manner, even in the same experimental group, and probably are related with differences in ionic strength between cells.
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DISCUSSION
In this work, we have studied the effects of reducing GlialCAM expression in astrocytes, a recently identified MLC1 and ClC-2 subunit (18, 20) . Taking into account these new results presented here, we conclude that whereas GlialCAM is necessary for the targeting to astrocyte -astrocyte junctions of both MLC1 and ClC-2 (18, 20) , it has an additional role as an MLC1-chaperone. Based on the fact that the stabilization is observed in HeLa cells, that GlialCAM interacts directly with MLC1 (18) and that Glial-CAM stabilizes also ER retained folding mutant variants of MLC1 (18), we propose that GlialCAM may protect MLC1 from ER-associated degradation. We hypothesize that this ER-protective effect of GlialCAM was not previously recognized due to the presence of endogenous GlialCAM expression in all the cell lines studied. Thus, it can be seen how expression of MLC1 in astrocytes without GlialCAM resulted in no plasma membrane staining of MLC1. As expression of MLC1 in astrocytes alone is able to arrive to the plasma membrane, it suggests that astrocytes should have an excess of endogenous GlialCAM compared with MLC1. It has been shown that MLC-related mutations in GlialCAM do not substantially affect the interaction with MLC1 (18) . Here, we also show that MLC-related GlialCAM variants are able to stabilize MLC1 protein, although they are not able to direct MLC1 to astrocyte junctions.
Reduction in both GlialCAM and MLC1 led to astrocyte vacuolation and a decreased VRAC activity (14) . The function of VRAC currents which are heterogeneous is related with the efflux of water during the regulatory volume response (36) . A decreased VRAC activity may cause an increase of intracellular water. We suggest that astrocyte vacuolation could be a consequence of increased water content, as blocking VRAC or the presence of a hypoosmotic medium (15) led to a similar type of vacuolation of endosomal origin. However, it is not clear how increased water content causes the appearance of vacuoles. It could be that astrocytes, which are cells evolutionary adapted to live in changing osmotic conditions, have gained the ability to keep the excess of intracellular water in the form of a vacuole, as happens in other organisms that form contractive vacuoles, and then they can survive in extracellular changing conditions (37 -41) .
How MLC1 and GlialCAM are related to VRAC activity? At this moment, it is very difficult to provide a clear answer to this question, as the function of MLC1 is unknown and the protein(s) responsible for VRAC activity still have to be discovered (27) . Identification of the VRAC channel is a major and difficult task, as revealed by the reports of many potential candidates that later turned out to be wrong, such as ICln, p-Glycoprotein or the ClC-3 transporter (27, 36) . GlialCAM may affect VRAC activity due to the lack of MLC1, as GlialCAM over-expression by itself cannot compensate the vacuolation caused by the lack of MLC1. However, we believe that it is unlikely that MLC1 is directly responsible of VRAC, as VRAC activity is present in all the cells of the body (36), whereas MLC1 is mostly restricted to the brain and no other MLC1-homologous genes exists in mammals (7) . In addition, VRAC activity is still present in astrocytes depleted of MLC1. MLC1 may affect VRAC activity indirectly, for instance, by modifying the adhesion strength of astrocytes or by affecting water or chloride handling in the brain. In this sense, aquaporin 4 depletion has also been shown to affect VRAC activity (42) . It is worth to mention that MLC1 protein has also been found surrounding the endosomal membranes of astrocytes treated with a hypoosmotic solution (15) or with blockers such as DCPIB or Bumetanide (this work, data not shown). In these endosomal vesicles, MLC1 could contribute to the formation of water vacuoles by regulating water and/or chloride fluxes.
Interestingly, although GlialCAM proteins containing MLC-related mutations re-establish MLC1 protein expression, they do not direct MLC1 to junctions and are not able to rescue the vacuolation defect caused by the lack of MLC1. Therefore, we suggest that the correct localization of MLC1 is critical to perform its physiological function. In relation with putative roles suggested for MLC1 in ion transport or adhesion (10, 14) , its localization in junctions may be needed to allow transcellular fluxes of solutes or to detect easily changes in adhesion strength.
No treatment exists yet for MLC disease (1) . Although the role of MLC1 is unknown, over-expression of GlialCAM rescues the vacuolation and the VRAC activity defect caused by some MLC1 mutants. Thus, the present data suggest that therapeutic strategies aimed at improving the surface expression of MLC1 or increasing the activity of VRAC may be envisaged as beneficial for MLC patients. This could be done by isolating pharmacological chaperones based on increased MLC1 plasma membrane expression (43) or molecules aimed to increase VRAC activity, as has been done for other chloride channels (44) .
MATERIALS AND METHODS
Primary culture, adenoviral transduction and vacuolation analysis
Rat primary quiescent astrocyte cultures were prepared as described previously from P0-P2 pups (13) . Dibutyryl-cAMP differentiated rat astrocytes, which were used for electrophysiological measurements, were obtained as described (29) . Adenoviruses expressing three copies of the flag epitope fused to human GlialCAM, either wild-type or containing the MLC-related mutations R92Q or R92W have been described (17) . Similarly, adenoviruses expressing HA-tagged wild-type MLC1 or containing the MLC-related mutations S246R or P92S were also constructed. Transduction of astrocytes was performed as already described (25) .
To study the vacuolation of astrocytes, we counted the cells with showed clear vacuoles. A cell was positive for vacuolation if have at least three vacuoles of a size bigger than 0.5 mm. The minor vacuolation observed in astrocytes transduced with the corresponding group expressing SCR shRNA instead of the specific shRNA was subtracted from all the experimental groups. This was done to compare directly MLC1 and GlialCAM depleted astrocytes, as the multiplicity of infection was different between both groups (MOI 5 for shRNA MLC1 and MOI 10 for shRNA GlialCAM) and the day of processing after the infection (5 days for shRNA MLC1 and 7 days for shRNA GlialCAM).
RNA interference and RT-qPCR
RNAi entry-clone (Gateway, Invitrogen) vectors were prepared using the Block-it PolII miR RNAi EmGFP expression vector kit following manufacturer's instructions. Entry clones were Human Molecular Genetics, 2013, Vol. 22, No. 21 4413 recombinated using LR clonase into the vector pAdVD EST-CMV/V5. Adenoviruses were produced and titrated using fluorescence microscopy detecting EmGFP which is expressed together with the shRNA. The adenoviruses expressing a negative control shRNA (shRNA SCR, scrambled) or expressing an shRNA directed against rat MLC1 (shRNA 905) were described previously (13) . The sequence of the oligos used to knockdown rat GlialCAM expression was: shRNA Glial1 (shRNA 1392):
′ and shRNA Glial2 (shRNA 908): 5 ′ tatagagcgccattggattctgtttt ggccactgactgacagaatccaggcgctctata3 ′ . Total RNA was prepared from a 10 cm culture plate using NucleoSpin RNA/Prot (Macherey -Nagel) as indicated by the manufacturer. RNA concentration was determined in a Nanodrop spectrophotometer. All samples had an A260/A280 ratio .1.8. RNA was stored at 2808C until further use. Eight hundred to 1000 ng of total RNA were reverse-transcribed with Transcriptor First Strand cDNA synthesis kit (Roche) following manufacturer's instructions at 258C for 10 min followed by 508C for 60 min, using random hexamers as primers. cDNA was stored at 2808C. qPCR was performed with Lightcycler 480 probes master kit (Roche) following manufacturer's instructions in a final volume of 10 ml, with cDNA at 1:10 dilution. The primers and UPL probes used were designed with the ProbeFinder version 2.45 (Roche) by the on-line application (https:// www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?Id= UP030000) considering exon spanning and covering all splicing species and have been previously indicated (13) . qPCR was run in a LightCycler 480 II on 384 well plates with the settings previously indicated. Efficiency curves were used for each of the analyzed genes and relative gene expression for each sample was calculated using ACTB (actin) as reference after testing its suitability for the experimental setup. All amplifications were inside the linear range. Data came from six different astrocyte preparations. Means of triplicates were used for each analysis. The standard deviation of the triplicates was 0.2 or lower. Data analysis was made with LightCycler 480 SW 1.5 software (Roche) and MS-Excel and MS-Access 2007. Significance was calculated using a Bootstrap method (45) , BootstRatio (http://regstattools.net/br), using the 'with control sample' condition and following tool instructions. Scrambled was used as a control sample.
For HeLa cells knockdown, constitutive (pGIPZ) lentivirus vectors, encoding shRNAmir-adapted short hairpin RNA specific for GlialCAM (GIPZ, V2LMM_69402 and V3LHS_413353), non-targeted variant (NT, ATCTCGCTTGGGCGAGAG-TAAG), were obtained from Thermo Scientific, OpenBiosystems (USA). Lentivirus was produced and HeLa cells were transduced as described (46) .
Immunofluorescence, western and surface expression studies in cells
For immunofluorescence staining, cells were fixed and processed as previously described (25) . Antibodies used were the following: anti-GlialCAM [1:100, (17) ], anti-MLC1 [1:100, (10)], anti-Occludin (1:100, Zymed), anti-b-Catenin (1:250, BD Transduction Lab), anti-Connexin 43 (1:100, Zymed) and anti-EEA1 (early endosomal antigen 1) (1:100, AbCAM). For WB studies, astrocyte lysates were prepared and processed as previously described (25) . b-Actin protein levels were used as a loading control. To quantify signals by WB, we performed at least three expositions of all WBs, to ensure linearity. Scanned images were quantified using Multigauge software (Fujifilm) or the freely available Image J program (http://rsbweb.nih.gov/ij/) with similar results. Surface expression in transfected mammalian cells or astrocytes was performed as previously described (25) .
In HeLa cells, the PM density of MLC1 and GlialCAM knockdown efficiency were determined by ELISA-based assay. HeLa cells expressing shGlialCAM or shSCR were trasfected with MLC1 cDNA constructs with Lipofectamine 2000 (Invitrogen, USA) 72 h prior to analysis. Cells were seeded on 24 well plates 20 h after transfection and incubated at 378C for 24 h. Cells were temperature rescued at 268C for 24 h, and unfolding was performed at 378C for 1 h prior of experiment. Primary and secondary Abs were bound on ice in DMEM containing 5% bovine serum (Gibco, USA). The extracellular epitope was detected with mouse anti-human HepaCAM (1:1000, R&D Systems, USA) and mouse anti-HA (1:1000 cl11, Covance, Canada) antibodies. Excess antibody was washed away and specific binding was determined by HRP-conjugated secondary Ab (Amersham Biosciences, Canada) with Amplexw Red (Invitrogen) as a substrate. The fluorescence intensity was measured from quadruplicate samples using a Infinite 1000 m PRO (Tecan Group Ltd, USA) fluorescence plate-reader at 544 nm excitation and 590 nm emission wavelengths. Total Ab binding was corrected with non-specific Ab binding, determined in mock transfected cells.
For immunoblotting, the cells were lysed in RIPA buffer containing 10 mM MG132, 10 mg/ml pepstatin + leupeptin, 1 mM phenylmethylsulfonyl fluoride and 5 mM N-ethylmaleimide. Polypeptides were separated by SDS-PAGE and probed by immunoblotting using Supersignal Western Pico (Pierce, USA). Na + -K + -Atpase (1:500, Santa Cruz, USA) was used as a loading control.
Patch-clamp experiments of astrocytes
Three days before the experiment, dB-cAMP differentiated astrocytes were trypsinized and replated at a density of 1-to 3 × 10 4 onto 24-well plates containing a glass cover slip with DMEM supplemented medium and 250 mM dB-cAMP. For electrophysiological recordings, the glass cover slip was mounted on the stage of an inverted microscopy equipped with phasecontrast optics and fluorescence illumination. Patch pipettes were pulled from borosilicate glass capillaries (Clark Electromedical, UK) and used after fire polishing (Narishige, Japan). Electrophysiological recordings were performed with a patch-clamp amplifier (Axopatch 200B, Molecular Devices, Union City, CA, USA) Patch electrodes were fabricated in a Flaming/Brown micropipettepuller P-97 (Sutter instruments). Electrodes had a resistance between 4 and 5 MV when filled with intracellular solution (in mM): 144 NMDG-Cl, 2 MgCl 2 , 5 EGTA, 5 HEPES at pH 7.3 and 308 + 2 mOsm/kg. Extracellular solution contained (in mM): 144 NMDG-Cl, 2 CaCl 2 , 2 MgCl 2 , 5 HEPES, 5 glucose at pH 7.4 and 310+3 mOsm/kg. Hypotonic extracellular solution (225%) was prepared by decreasing NMDG-Cl concentration to 105 mM (229+2 mOsm/kg). All solution osmolarities were adjusted with sorbitol. An Ag/AgCl ground electrode
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Human Molecular Genetics, 2013, Vol. 22, No. 21 mounted in a 3 M KCl agar bridge was used. Membrane currents were recorded in the whole-cell patch clamp configuration, filtered at 2 kHz, digitized at 10 kHz and acquired with pClamp 9 software (Molecular Devices). Data were analyzed with Clampfit 9 (Molecular Devices) and Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). Whole-cell capacitance and series resistance were compensated with the amplifier circuitry. Series resistance was always kept below 10 MV and compensated at 70-80%. All recordings were performed at room temperature (22 -238C). Currents were evoked with 4 s pulses from +80 to 2120 mV from a holding potential of 0 mV.
